CHASKA, Minn., April 08, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 12th Annual American Biomanufacturing Summit. The conference will take place April 14 - 15, 2026, in San Francisco, CA.
Details regarding Lifecore’s participation are as follows:
12th Annual American Biomanufacturing Summit
Details: Lifecore team will be present to discuss process development and manufacturing services for injectables programs.
Booth number: 41
Conference Dates: April 14 - 15, 2026
Location: Hyatt Regency San Francisco Airport, San Francisco, CA
If you are interested in meeting with Lifecore during this event, please reach out to us at: [email protected].
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.
Contact Information:
Vida Strategic Partners
Stephanie Diaz (Investors)
415-675-7401
[email protected]\
Jennifer Arcure (Media)
917-603-0681
[email protected]
Lifecore Biomedical
Ryan D. Lake (CFO)
952-368-6244
[email protected]